This year, Firalis/Amoneta Diagnostics is once again participating in the AD/PD™ conference, which will be held in Copenhagen from March 17 to March 21, 2026. It is a major international event that brings together experts in the field of Alzheimer’s and Parkinson’s diseases.
Spotlight on APO-Easy®: A Genotyping Solution for Alzheimer’s Risk Assessment
At this year’s congress, we will highlight APO-Easy® Genotyping kit, our CE-IVDR certified and De Novo-cleared by the FDA test designed to assess genetic risk for Alzheimer’s disease through analysis of the Apolipoprotein E (APOE) gene.
Alzheimer’s disease is a complex and multifactorial condition influenced by both genetic and environmental factors. Among known genetic markers, the APOE gene plays a central role, with three main variants: APOE ε2, APOE ε3, and APOE ε4. The APOE ε4 allele is associated with an increased risk of developing Alzheimer’s disease, particularly in individuals carrying one or two copies.
With the recent approval and launch of innovative anti-amyloid therapies such as Leqembi® and Kisunla®, identifying the right patients has become more critical than ever.
These treatments are primarily indicated for individuals with confirmed amyloid pathology. However, their use requires careful consideration in APOE ε4 carriers due to a higher risk of ARIA (Amyloid-Related Imaging Abnormalities).
In this evolving therapeutic landscape, APO-Easy® provides a simple, reliable, and non-invasive solution to detect the APOE ε4 allele.
APO-Easy® supports accurate genetic stratification, helping clinicians identify patients who may benefit from specific therapies and make more informed treatment decisions.
NeuroDeGene®: A Genetic Panel for Neurodegenerative Diseases
Neurodegenerative diseases are complex disorders in which genetic factors play an important role. However, early diagnosis remains challenging, and current diagnostic methods often rely on invasive procedures such as cerebrospinal fluid (CSF) sampling or expensive imaging techniques like PET scans.
At AD/PD™ 2026, Firalis/Amoneta Diagnostics will also present NeuroDeGene®, a DNA-targeted sequencing panel developed in partnership with Celemics, Inc.. The panel detects single-nucleotide polymorphisms (SNPs) and insertions/deletions (INDELs) associated with several neurodegenerative diseases.
NeuroDeGene® includes more than 15,000 variants across 19 diseases, with a strong focus on non-coding variants, which represent about 70% of the panel. Using next-generation sequencing (NGS) and dedicated bioinformatics analysis, it helps explore genetic variants associated with neurodegenerative diseases and can support research, early detection, and patient stratification.
The kit is currently being further developed and clinically validated as part of a Eurostars Programme project, carried out in collaboration with French and Turkish partners.
Visit Us at Booth #23
We are excited to showcase APO-Easy® at AD/PD™ 2026 and explore how this product, in conjunction with emerging therapies like Leqembi and Kisunla, is shaping the future of Alzheimer’s care.
We invite you to visit our booth#23 to learn more about APO-Easy® and our other diagnostic solutions